A study about how well emicizumab prevents bleeding in haemophilia A patients and its overall impact on their health outcomes

To Study Efficacy and Outcome of Emicizumab Prophylaxis in Patients of Hemophilia A - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/069770

Enrollment

Registered

2024-07-01

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D66- Hereditary factor VIII deficiency

Interventions

Intervention1: Emicizumab: Initial 1 month - 3mg/ kg weekly Then 6mg /kg per month Control Intervention1: Factor viii Recombinant factor: Continue same treatment 40- 50 IU/ kg

Eligibility

Inclusion criteria

Inclusion criteria: New Confirmed case of hemophilia A Patients with a documented baseline bleeding frequency, allowing for a comparison of bleeding episodes before and after emicizumab treatment Patients who give informed consent

Exclusion criteria

Exclusion criteria: Presence of coagulation disorders other than hemophilia A, which may confound the study results Significant comorbidities or medical conditions that may independently affect the outcomes of interest. Like liver diseases Patients without proper informed consent

Design outcomes

Primary

Measure	Time frame
Reducing bleeding events in haemophilia A patient And evaluating efficacy of emicizumab Timepoint: 6 months	—

Secondary

Measure	Time frame
Reducing auto antibodies formationTimepoint: 1 months	—

Countries

India

Contacts

Public ContactDr R L Suman

Rnt medical collage udaipur

sumanrl@yahoo.co.in9414155775

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026